In the latest trading session, DexCom (DXCM - Free Report) closed at $119.30, marking a +0.35% move from the previous day. This change outpaced the S&P 500's 0% on the day. Elsewhere, the Dow lost 0.05%, while the tech-heavy Nasdaq lost 0.21%.
Heading into today, shares of the medical device company had lost 19.38% over the past month, lagging the Medical sector's gain of 1.69% and the S&P 500's gain of 5.49% in that time.
Wall Street will be looking for positivity from DXCM as it approaches its next earnings report date. This is expected to be May 1, 2019. On that day, DXCM is projected to report earnings of -$0.17 per share, which would represent year-over-year growth of 46.88%. Our most recent consensus estimate is calling for quarterly revenue of $246.45 million, up 33.65% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.46 per share and revenue of $1.23 billion. These totals would mark changes of +53.33% and +19.13%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DXCM. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DXCM is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, DXCM is currently trading at a Forward P/E ratio of 256.11. For comparison, its industry has an average Forward P/E of 33.45, which means DXCM is trading at a premium to the group.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.